Skip to main content

Advertisement

SpringerLink
Log in

Successful cessation of lamivudine using interferon in a patient with chronic hepatitis B who received prophylactic lamivudine treatment during chemotherapy

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Lamivudine (LMV) prophylaxis is effective in preventing hepatitis B virus (HBV) reactivation in patients with chronic hepatitis B undergoing chemotherapy. However, the optimal duration of LMV prophylaxis remains unclear. We report herein the case of a woman with localized follicular B-cell lymphoma who received chemotherapy with LMV prophylaxis. She achieved complete response to lymphoma, and LMV treatment was continued for 8 months after completion of chemotherapy. HBV status was still inactive. LMV was then stopped, but reactivation of hepatitis developed 1 month after cessation of LMV. LMV was restarted, resulting in successful treatment of reactivated hepatitis. Interferon (IFN) was used for 6 months before withdrawal of LMV, which was successfully ceased without flare hepatitis. This report describes the utility of sequential therapy with LMV and IFN to treat flare after withdrawal of LMV in hepatitis B carriers who receive LMV prophylaxis during chemotherapy and to prevent flare after withdrawal of LMV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395–403.

    Article  PubMed  Google Scholar 

  2. Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.

    Article  CAS  PubMed  Google Scholar 

  3. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96:447–9.

    Article  CAS  PubMed  Google Scholar 

  4. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncology. 1999;7:394–8.

    Article  Google Scholar 

  5. Yeo W, Chan PKS, Zhong S, Ho WM, Steimberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patient undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307.

    Article  CAS  PubMed  Google Scholar 

  6. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51:597–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.

    Article  CAS  PubMed  Google Scholar 

  8. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.

    Article  CAS  PubMed  Google Scholar 

  9. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med. 1999;341:1256–63.

    Article  CAS  PubMed  Google Scholar 

  10. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172–80.

    Article  CAS  PubMed  Google Scholar 

  11. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.

    Article  CAS  PubMed  Google Scholar 

  12. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.

    Article  CAS  PubMed  Google Scholar 

  13. Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004;19:323–9.

    Article  CAS  PubMed  Google Scholar 

  14. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.

    Article  CAS  PubMed  Google Scholar 

  16. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002;100:391–6.

    Article  CAS  PubMed  Google Scholar 

  17. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702–9.

    Article  CAS  PubMed  Google Scholar 

  18. Idilman R, Arat M, Soydan E, Törüner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat. 2004;11:141–7.

    Article  CAS  PubMed  Google Scholar 

  19. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.

    Article  CAS  PubMed  Google Scholar 

  20. Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, et al. Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology. 2008;48:1–10.

    Article  PubMed  Google Scholar 

  21. Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res. 2007;8:661–6.

    Article  Google Scholar 

  22. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–95.

    Article  CAS  PubMed  Google Scholar 

  23. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouillères O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology. 2001;34:573–7.

    Article  CAS  PubMed  Google Scholar 

  24. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005;100:2463–71.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan

    Kazuhiko Hayashi, Yoshiaki Katano, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano & Hidemi Goto

Authors
  1. Kazuhiko Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiaki Katano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masatoshi Ishigami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akihiro Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiki Hirooka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Isao Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hidemi Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiaki Katano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayashi, K., Katano, Y., Ishigami, M. et al. Successful cessation of lamivudine using interferon in a patient with chronic hepatitis B who received prophylactic lamivudine treatment during chemotherapy. Clin J Gastroenterol 2, 210–213 (2009). https://doi.org/10.1007/s12328-009-0065-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12328-009-0065-0

Keywords

Search

Navigation